Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.

NCT02770261 is registered in ClinicalTrials.gov with Alvogen Korea as lead sponsor.

NCT NCT02770261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02770261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.
Lead sponsor
Alvogen Korea
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
October 31, 2016
Enrollment
219 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholesterolemia, hypertension